再鼎醫藥(09688.HK):第三季度產品收入6920萬美元
格隆匯11月8日丨再鼎醫藥(09688.HK)發佈公吿,2023年第三季度的產品收入為6920萬美元,2022年同期為5700萬美元,同比增長22%,按固定匯率計算同比增長27%。產品收入增加主要是由於銷量的增加、衞偉迦的上市以及COVID-19疫情負面影響的減少。衞偉迦®(艾加莫德α注射液)自9月在中國商業化上市以來,實現銷售收入490萬美元。
再鼎醫藥創始人、董事長兼首席執行官杜瑩博士表示:“2023年第三季度,我們實現了多個重要里程碑,包括在中國成功上市衞偉迦用於治療全身型重症肌無力(gMG)患者,以及艾加莫德用於慢性炎性脱髓鞘性多發性神經根神經病(CIDP)的關鍵性臨牀研究取得陽性結果。這些進展突顯了我們堅定不移為亟需患者提供創新藥物的承諾。國家藥品監督管理局(NMPA)正在審評審批我們的多個新藥上市申請和正在進行的具有重大市場潛力藥物的關鍵性臨牀研究,我們擁有良好優勢,以加速我們的管線進展和拓展我們商業化產品組合,為全球患者帶來更多福祉。”
再鼎醫藥總裁兼首席運營官Josh Smiley表示:“我們的商業化團隊面對第三季度宏觀層面的挑戰,仍實現了同比27%的產品淨收入增長(以固定匯率計算)。則樂仍然是中國內地卵巢癌領域院內銷售領先PARP抑制劑;作為一款有望改變中國gMG患者治療模式的藥物,衞偉迦的商業化上市已展現出令人興奮的趨勢。預計在未來兩到三年內,再鼎至少還將有額外的7款產品上市,有望貢獻重要的收入增長。隨着業務增長與運營效率的提高,將有助於我們在未來實現盈利。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.